NeuroThera Labs, which is majority-owned by SciSparc (SPRC), has entered into an agreement to acquire approximately 54.01% of CliniQuantum (CliniQ). CliniQ is a quantum technology company focused on developing a next-generation platform for clinical trials using quantum computing. The acquisition involves NeuroThera issuing common shares valued at approximately $9.46 million to CliniQ’s selling shareholders, with potential earn-out payments up to an additional $2.5 million based on specific milestones.
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum
NeuroThera Labs, which is majority-owned by SciSparc (SPRC), has entered into an agreement to acquire approximately 54.01% of CliniQuantum (CliniQ). CliniQ is a quantum technology company focused on developing a next-generation platform for clinical trials using quantum computing. The acquisition involves NeuroThera issuing common shares valued at approximately $9.46 million to CliniQ’s selling shareholders, with potential earn-out payments up to an additional $2.5 million based on specific milestones.